Literature DB >> 9603473

Expression in cytotoxic T lymphocytes of a single-chain anti-carcinoembryonic antigen antibody. Redirected Fas ligand-mediated lysis of colon carcinoma.

P K Darcy1, M H Kershaw, J A Trapani, M J Smyth.   

Abstract

In the MD45 mouse cytotoxic T lymphocyte (CTL) hybridoma cell line, we have expressed a chimeric receptor, consisting of the single-chain variable domains (scFv) of anti-carcinoma embryonic antigen (CEA) mAb linked to Fcgamma receptor (FcgammaR) chain via a CD8 hinge. Transfected MD45 subclones lysed CEA-positive human colon carcinoma cell lines in an antigen-specific and FasL-dependent manner. The degree of lysis correlated with the level of chimeric receptor expressed on transduced MD45 subclones. The requirement for an intact Y65TGL motif in the signaling gamma chain suggested that interaction of the chimeric receptor with target cell CEA induced the cytotoxicity of MD45-scFv subclones. However, MD45 expressing a Y65F mutant chimera still displayed minor levels of lysis following PMA stimulation, suggesting that PMA could bypass gamma chain induction of functional FasL. Pretreatment of Fas-resistant CEA-positive colon carcinoma target cells with IFN-gamma increased their sensitivity of MD45-scFv subclones and FasL-mediated lysis. This study has demonstrated the successful activation of FasL function via a chimeric receptor introduced into lymphocytes and the susceptibility of human colon carcinoma to combined cytokine and CTL treatment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9603473     DOI: 10.1002/(SICI)1521-4141(199805)28:05<1663::AID-IMMU1663>3.0.CO;2-L

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  12 in total

1.  Emerging CAR T cell therapies: clinical landscape and patent technological routes.

Authors:  Virgínia Picanco-Castro; Cristiano Gonçalves Pereira; Kamilla Swiech; Kelen Cristina Ribeiro Malmegrim; Dimas Tadeu Covas; Geciane Silveira Porto
Journal:  Hum Vaccin Immunother       Date:  2019-12-06       Impact factor: 3.452

Review 2.  Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy.

Authors:  Carlos A Ramos; Gianpietro Dotti
Journal:  Expert Opin Biol Ther       Date:  2011-04-04       Impact factor: 4.388

Review 3.  Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.

Authors:  Marc Cartellieri; Michael Bachmann; Anja Feldmann; Claudia Bippes; Slava Stamova; Rebekka Wehner; Achim Temme; Marc Schmitz
Journal:  J Biomed Biotechnol       Date:  2010-05-05

Review 4.  Strategies to genetically engineer T cells for cancer immunotherapy.

Authors:  Timothy T Spear; Kaoru Nagato; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2016-05-02       Impact factor: 6.968

Review 5.  Engineered T cells for cancer treatment.

Authors:  Usanarat Anurathapan; Ann M Leen; Malcolm K Brenner; Juan F Vera
Journal:  Cytotherapy       Date:  2013-11-13       Impact factor: 5.414

6.  Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging.

Authors:  Konstantin Dobrenkov; Malgorzata Olszewska; Yury Likar; Larissa Shenker; Gertrude Gunset; Shangde Cai; Nagavarakishore Pillarsetty; Hedvig Hricak; Michel Sadelain; Vladimir Ponomarev
Journal:  J Nucl Med       Date:  2008-06-13       Impact factor: 10.057

Review 7.  Treatment of lymphoma with adoptively transferred T cells.

Authors:  Brian G Till; Oliver W Press
Journal:  Expert Opin Biol Ther       Date:  2009-11       Impact factor: 4.388

Review 8.  Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions.

Authors:  Kevin J Curran; Hollie J Pegram; Renier J Brentjens
Journal:  J Gene Med       Date:  2012-06       Impact factor: 4.152

9.  T cell avidity and tumor recognition: implications and therapeutic strategies.

Authors:  Mark D McKee; Jeffrey J Roszkowski; Michael I Nishimura
Journal:  J Transl Med       Date:  2005-09-20       Impact factor: 5.531

10.  Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection.

Authors:  A G Heriot; J B Marriott; S Cookson; D Kumar; A G Dalgleish
Journal:  Br J Cancer       Date:  2000-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.